Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 9/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | KRAS | P01116 | 1/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.36 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3416856 | 1.00 | LRRK2 (0.43) | LRRK2AKT1PIK3CAMTORGRM4 | |
| SCHEMBL3416862 | 1.00 | LRRK2 (0.43) | LRRK2AKT1PIK3CAMTORGRM4 | |
| SCHEMBL3415110 | 0.91 | GRM4 (0.39) | LRRK2AKT1PIK3CAMTORGRM4 | |
| SCHEMBL3415107 | 0.91 | GRM4 (0.39) | LRRK2AKT1PIK3CAMTORGRM4 | |
| SCHEMBL18072381 | 0.91 | HDAC6 (0.44) | LRRK2PIK3CAGRM4NUDT1HDAC6 | |
| SCHEMBL3411667 | 0.87 | NUDT1 (0.44) | NUDT1 | |
| SCHEMBL24983084 | 0.83 | LRRK2 (0.44) | LRRK2GRM4HDAC6KRASSOS1 | |
| SCHEMBL30849530 | 0.83 | LRRK2 (0.44) | LRRK2GRM4HDAC6KRASSOS1 | |
| SCHEMBL30849531 | 0.83 | LRRK2 (0.44) | LRRK2GRM4HDAC6KRASSOS1 | |
| SCHEMBL24983232 | 0.83 | LRRK2 (0.44) | LRRK2GRM4HDAC6KRASSOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3060563-B1 | RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2018-05-02 | — | — | EP | disclosed |
| US-9896449-B2 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| US-20170066766-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2017-03-09 | — | — | US | disclosed |
| US-9533988-B2 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2017-01-03 | — | — | US | disclosed |
| EP-3060563-A1 | RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | Novartis AG (CH) | 2016-08-31 | — | — | EP | disclosed |
| US-20160102092-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2016-04-14 | — | — | US | disclosed |
| US-9266883-B2 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2016-02-23 | — | — | US | disclosed |
| WO-2015059668-A1 | RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2015-04-30 | — | — | WO | disclosed |
| US-20150119385-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119385-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | LRRK2 569/4885AKT1 2047/4885PIK3CA 59/4885 |
| US-20160102092-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | LRRK2 569/4885AKT1 2047/4885PIK3CA 59/4885 |
| US-20170066766-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | LRRK2 569/4885AKT1 2047/4885PIK3CA 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.